GALK1 Modulators Restore PTEN/AKT Pathway Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The PTEN/AKT signaling pathway is frequently hyperactivated in various human cancers, leading to enhanced cell proliferation, survival, and motility, and is often impaired due to mutations or deletions in the PTEN tumor suppressor gene, which are common in cancers such as melanoma, breast, lung, and prostate tumors, necessitating the identification of novel modifiers to restore pathway function.
Innovation Solution
Discovery of the Galactose Kinase 1 (GALK1) gene as a modifier of the PTEN/AKT pathway, with methods developed to identify and utilize GALK1-modulating agents that can restore PTEN/AKT function, including assays to detect changes in GALK1 expression or kinase activity, and the use of GALK1-modulating agents like small molecules, antibodies, and nucleic acid modulators to inhibit or enhance GALK1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PTEN tumor suppressor gene is mutated or deleted, then AKT signaling pathway becomes hyperactivated leading to enhanced cell proliferation and survival, but the pathway function becomes impaired and cannot be restored by conventional means
Solution Approach 1:
The patent introduces GALK1 as an intermediary molecule that modulates the PTEN/AKT pathway. GALK1 acts as a mediator between galactose metabolism and the signaling pathway, where its kinase activity influences AKT phosphorylation status. By targeting GALK1 with modulating agents, the pathway function can be restored without directly addressing the PTEN mutation, thus resolving the contradiction through an intermediate target.
Solution Approach 2:
The patent employs parameter changes by modulating GALK1 kinase activity through various agents (inhibitors or activators). By changing the kinetic parameters of GALK1, the downstream AKT signaling is indirectly regulated, allowing restoration of pathway function despite PTEN gene mutations. This approach transforms the fixed defective state into a可调 state through parameter modulation.
2Adaptability or versatility
If novel modifiers like GALK1 are identified to modulate the PTEN/AKT pathway, then therapeutic options are expanded, but the complexity of identifying and characterizing these modifiers increases
Solution Approach 1:
The patent segments the complex pathway modulation task into manageable components: (1) identifying GALK1 as the target modifier, (2) developing specific kinase activity assays to measure GALK1 function, (3) screening for modulating agents against GALK1, and (4) validating pathway restoration. This segmentation reduces the overall complexity by breaking down the versatile therapeutic goal into discrete, testable steps.
Solution Approach 2:
The patent replaces complex cellular-level observations with simplified biochemical assays. Instead of directly measuring AKT pathway activity in whole cells (which is complex), the invention uses in vitro kinase assays to measure GALK1 activity, providing a simpler, more direct readout that can be easily screened and quantified, thus reducing assay complexity while maintaining therapeutic relevance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for the identification of candidate therapeutic agents that can modulate the PTEN/AKT pathway, potentially treating disorders associated with defective PTEN/AKT function, such as cancer, by restoring normal pathway activity and affecting cell proliferation, apoptosis, and angiogenesis.
Implementation Method 1
GALK1 converts galactose into galactose-1-phosphate which then feeds into glycolysis
Implementation Method 2
PTEN dephosphorylates the D3 position of PIP3 and downregulates signaling events dependent on PIP3 levels
Implementation Method 3
phosphatidylinositol (3, 4) bisphosphate (PIP2) is phosphorylated by phosphatidylinositol 3-kinase (PI3K) to generate PIP3
Data Source
AI summary
Human GALKl genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of GALKl are provided.